VolitionRx Limited (NYSE AMERICAN: VNRX) received €2.0 million ($2.3 million) in non-dilutive funding from Belgian regional government agencies Namur Invest and Wallonie Entreprendre S.A., according to a company statement.

The epigenetics company will use the proceeds to develop its Nu.Q product portfolio, including regulatory transition work for Nu.Q NETs from IVDD to IVDR standards and research into a Lateral Flow product for Low Income Countries access.

The funding will be distributed in tranches, with approximately $0.4 million received in December 2025, $1 million in the first quarter of 2026, and the remaining $0.9 million over the next 12 months based on time and event milestones.

"This is a key part of our financing strategy to actively seek non-dilutive funding, as this provides additional cash at favorable terms to support the Company's continued development and anchorage in Wallonia," said Dr. Gaetan Michel, Chief Operating Officer of Volition.

The company stated this latest funding brings its total non-dilutive funding from all sources to over $25 million.

Nicolas Delahaye, Corporate Relations Manager at Namur Invest, said the funding aims to help Volition expand manufacturing capabilities and anchor research and development efforts in Wallonia. Géry Lefebvre, Investment Manager at Wallonie Entreprendre S.A., indicated the financing supports clinical validation and commercialization expansion.

VolitionRx develops blood-based diagnostic tests for disease detection and monitoring, with research and development activities centered in Belgium and offices in the U.S. and London.